Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2006 Jan;50(1):43-8.
doi: 10.1128/AAC.50.1.43-48.2006.

Multidrug-resistant Pseudomonas aeruginosa: risk factors and clinical impact

Affiliations

Multidrug-resistant Pseudomonas aeruginosa: risk factors and clinical impact

Valerie Aloush et al. Antimicrob Agents Chemother. 2006 Jan.

Abstract

Pseudomonas aeruginosa, a leading nosocomial pathogen, may become multidrug resistant (MDR). Its rate of occurrence, the individual risk factors among affected patients, and the clinical impact of infection are undetermined. We conducted an epidemiologic evaluation and molecular typing using pulsed-field gel electrophoresis (PFGE) of 36 isolates for 82 patients with MDR P. aeruginosa and 82 controls matched by ward, length of hospital stay, and calendar time. A matched case-control study identified individual risk factors for having MDR P. aeruginosa, and a retrospective matched-cohort study examined clinical outcomes of such infections. The 36 isolates belonged to 12 PFGE clones. Two clones dominated, with one originating in an intensive care unit (ICU). Cases and controls had similar demographic characteristics and numbers of comorbid conditions. A multivariate model identified ICU stay, being bedridden, having high invasive devices scores, and being treated with broad-spectrum cephalosporins and with aminoglycosides as significant risk factors for isolating MDR P. aeruginosa. Having a malignant disease was a protective factor (odds ratio [OR] = 0.2; P = 0.03). MDR P. aeruginosa was associated with severe outcomes compared to controls, including increased mortality (OR = 4.4; P = 0.04), hospital stay (hazard ratio, 2; P = 0.001), and requirement for procedures (OR = 5.4; P = 0.001). The survivors functioned more poorly at discharge than the controls, and more of the survivors were discharged to rehabilitation centers or chronic care facilities. The epidemiology of MDR P. aeruginosa is complex. Critically ill patients that require intensive care and are treated with multiple antibiotic agents are at high risk. MDR P. aeruginosa infections are associated with severe adverse clinical outcomes.

PubMed Disclaimer

Figures

FIG. 1.
FIG. 1.
Schematic representation of the spread of clone A, the major MDR P. aeruginosa clone, during a 13-week period. Each hospital ward is assigned a label. The day of isolation of the MDR P. aeruginosa is marked for each patient by the letter “A.”

References

    1. Bergmans, D. 1998. Cross-colonisation with Pseudomonas aeruginosa of patients in an intensive care unit. Thorax 53:1053-1058. - PMC - PubMed
    1. Carmeli, Y., G. M. Eliopoulos, and M. H. Samore. 2002. Antecedent treatment with different antibiotic agents as a risk factor for vancomycin-resistant Enterococcus. Emerg. Infect. Dis. 8:802-807. - PMC - PubMed
    1. Carmeli, Y., N. Troillet, G. Eliopoulos, and M. H. Samore. 1999. Emergence of antibiotic-resistant Pseudomonas aeruginosa: comparison of risks associated with different antipseudomonal agents. Antimicrob. Agents Chemother. 43:1379-1382. - PMC - PubMed
    1. Carmeli, Y., N. Troillet, A. W. Karchmer, and M. H. Samore. 1999. Health and economic outcomes of antibiotic resistant Pseudomonas aeruginosa. Arch. Intern. Med. 159:1127-1132. - PubMed
    1. Clinical and Laboratory Standards Institute. 2005. Performance standards for antimicrobial susceptibility testing. Fifteenth informational supplement M100-S15. Clinical and Laboratory Standards Institute, Wayne, Pa.

Publication types

LinkOut - more resources